Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70260 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL4177435 | 1.00 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL3512016 | 0.90 | HSD17B10 (0.47) | HSD17B10ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL3512019 | 0.90 | HSD17B10 (0.47) | HSD17B10ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL792043 | 0.90 | HSD17B10 (0.47) | HSD17B10ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5307883 | 0.89 | PDE8B (0.46) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL12485875 | 0.89 | PDE8B (0.46) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL5257475 | 0.89 | PDE8B (0.46) | HSD17B10HPGDATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL16611963 | 0.85 | PDE8B (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL16607569 | 0.85 | PDE8B (0.40) | HSD17B10CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023244788-A9 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2023244788-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-107892684-B | Quinazoline derivatives, pharmaceutical compositions thereof, and use as medicaments | 锦州奥鸿药业有限责任公司 | 2020-05-26 | — | — | CN | disclosed |
| EP-3022186-B1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2020-02-26 | — | — | EP | disclosed |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-08-21 | — | — | US | disclosed |
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | FOCHON PHARMACEUTICALS, LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9714235-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2017-07-25 | — | — | US | disclosed |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2016-06-16 | — | — | US | disclosed |
| EP-3022186-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | Shanghai Fochon Pharmaceutical Co. Ltd (CN) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015007219-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2015-01-22 | — | — | WO | disclosed |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267663-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | HSD17B10 4390/4885CHRM2 2327/4885CHRM1 2185/4885 |
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | HSD17B10 3186/4885CHRM2 2139/4885CHRM1 750/4885 |
| US-20160168129-A1 | QUINAZOLINE DERIVATIVES, COMPOSITIONS THEREOF, AND USE AS PHARMACEUTICALS | ABL1, MAP4K2, DMPK | HSD17B10 4390/4885CHRM2 2327/4885CHRM1 2185/4885 |
| US-10053449-B2 | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | ABL1, MAP4K2, DMPK | HSD17B10 4390/4885CHRM2 2327/4885CHRM1 2185/4885 |
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | HSD17B10 3762/4885CHRM2 4785/4885CHRM1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.